Wegovy

# Revolutionary Weight Loss: Wegovy's Impact Beyond the Scale

Explore the groundbreaking developments surrounding Wegovy (semaglutide) in this comprehensive podcast episode with Alexandra Reeves. Discover how this FDA-approved weight management medication is transforming healthcare across multiple dimensions - from surprising cardiovascular benefits independent of weight loss to its expanding use in pediatric patients. Learn about the upcoming oral formulation expected in 2025, evolving telehealth partnerships, and regulatory challenges shaping access to GLP-1 medications. The episode features fascinating insights into clinical data showing 15% average weight loss, with some patients achieving 20% reduction, alongside improvements in blood pressure, cholesterol, and blood sugar levels...

# Wegovy Revolution: The Data Behind 2025's Weight Loss Breakthrough - Health Insights Podcast

Explore the transformative impact of Wegovy (semaglutide) on America's obesity crisis in this comprehensive episode of Health Insights with Alexandra Reeves. Discover how this groundbreaking GLP-1 medication has contributed to the first decline in U.S. adult obesity rates in decades, from 40% to 37%, representing 7.6 million fewer Americans living with obesity.

This episode dives deep into the latest clinical research, including the landmark Lancet study revealing Wegovy's cardiovascular benefits independent of weight loss, and new data presented at the 76th Annual Liver Meeting on...

# Wegovy's Impact Beyond Weight Loss: New Research on MASH and Liver Health

Explore the latest breakthrough research on Wegovy (semaglutide 2.4mg) and its expanding applications beyond weight management. In this insightful episode, veteran health correspondent Alexandra Reeves takes you behind the scenes of Novo Nordisk's upcoming presentations at the 76th Annual Liver Meeting, where eleven new research abstracts will showcase Wegovy's promising effects on metabolic dysfunction-associated steatohepatitis (MASH).

Discover how this GLP-1 receptor agonist is revolutionizing treatment approaches for patients with obesity and liver conditions, with clinical data demonstrating significant improvements across diverse populations. Reeves navigates...

# Wegovy's Turbulent Journey: Balancing Promise and Controversy in Weight Management

In this compelling episode, host Alexandra Reeves delivers a comprehensive analysis of Wegovy's impact on the weight management landscape. From Costco's game-changing $599 monthly pricing to Novo Nordisk's staggering $8.66 billion income, the episode explores how this groundbreaking GLP-1 medication is transforming lives while generating significant controversy.

Dive into the concerning legal battles facing Wegovy, with nearly 3,000 lawsuits nationwide citing serious side effects including vision loss and kidney damage. Learn about the clinical data showing 75% of patients achieve meaningful weight loss, yet discover why over half discontinue treatment...

# The Wegovy Saga: Oral Pill Breakthrough, Legal Challenges, and Expanding Medical Frontiers

In this compelling episode of Alexandra Reeves' podcast, we dive deep into the latest developments surrounding Wegovy, the weight-loss medication transforming obesity treatment worldwide. From Novo Nordisk's groundbreaking oral formulation awaiting FDA approval to the mounting legal challenges facing the pharmaceutical giant, this comprehensive analysis covers the full spectrum of Wegovy's evolving story.

Discover the promising OASIS 4 trial results showing 13.6% average weight reduction with the new oral semaglutide, and learn about the expanding therapeutic applications beyond weight loss - including treatments for liver disease...

# Wegovy's Impact: Legal Battles, Competition, and New Research in Weight Management

Join host Alexandra Reeves as she examines the latest developments surrounding Wegovy, the groundbreaking weight management medication reshaping healthcare in 2025. This episode dives into recent FDA label updates, the growing wave of lawsuits alleging severe side effects, and Novo Nordisk's warning letter for misleading promotional practices. Discover how Wegovy compares to newer competitor Zepbound, explore Costco's pricing innovation making treatment more accessible at $499 monthly, and learn about promising research on oral semaglutide and potential Alzheimer's disease benefits. From courtroom drama to clinical trials, this comprehensive analysis reveals...

# The Wegovy Revolution: Medical Breakthrough or Legal Minefield? | Health Insights Podcast

In this eye-opening episode, we delve into the complex world of Wegovy, one of today's most talked-about weight loss medications. From Philadelphia courtrooms where thousands of lawsuits allege severe side effects to groundbreaking research showing both promising results and concerning risks, this comprehensive exploration covers everything you need to know about semaglutide drugs.

Discover the latest developments including:
- The surge in legal battles against pharmaceutical giant Novo Nordisk
- Alarming new studies revealing potential links to blood clots and vision loss
...

# Wegovy's Continuing Saga: Controversy, Competition, and Legal Battles in Weight Loss Medicine

Join host Alexandra Reeves as she delves into the complex world of Wegovy, the revolutionary weight loss medication that's transforming lives while facing mounting legal challenges. This comprehensive episode explores the intersection of modern medicine and society, examining how Wegovy's remarkable effectiveness—achieving over 15% weight loss in clinical trials—is now shadowed by serious concerns.

## What You'll Learn:
- The growing legal battle: Over 1,800 lawsuits including severe cases like Juanita Gantt, who required intestinal removal after complications
- Competitive landscape: How Eli Lill...

# Navigating the Wegovy Revolution: Breakthrough Approvals, Lawsuits, and Future Innovations

In this compelling episode, veteran journalist Alexandra Reeves unpacks the complex world of Wegovy (semaglutide), exploring its groundbreaking FDA approval for fatty liver disease treatment, the mounting legal challenges with over 2,600 lawsuits filed, and Novo Nordisk's surprising job cuts. Discover the promising results of Wegovy's new oral formulation, temporary price reductions making treatment more accessible, and the critical considerations for those thinking about discontinuing therapy. Reeves masterfully balances the excitement around Wegovy's cardiovascular benefits with growing concerns about side effects including gastroparesis and vision issues. Perfect for healthcare...

# Wegovy Update: New FDA Approval, Legal Battles, and Vision Loss Concerns

In this eye-opening podcast episode, Alexandra Reeves delivers the latest breaking news on Wegovy, the revolutionary weight loss medication transforming obesity treatment. Discover Wegovy's groundbreaking FDA approval for fatty liver disease (MASH) - the first GLP-1 drug authorized for this common condition affecting millions.

Reeves investigates the concerning surge in lawsuits against manufacturer Novo Nordisk, including shocking claims of permanent vision loss, gastroparesis, and blood clots allegedly linked to the medication. Learn about the FDA's new "green list" of overseas manufacturers amid counterfeit concerns and...

# The Next Frontier in Weight Loss: Wegovy in Pill Form - Expert Insights

Discover the groundbreaking developments in obesity treatment as host Alexandra Reeves explores the potential game-changer in weight management - Wegovy in pill form. This episode delves into the recently released OASIS 4 phase three trial results published in the New England Journal of Medicine, revealing impressive 16.6% average weight loss over 64 weeks compared to placebo's 2.7%.

Learn about Novo Nordisk's pending FDA decision that could revolutionize obesity treatment accessibility, potentially overcoming patient reluctance toward injections. The episode balances promising clinical outcomes with important safety considerations, including...

# The Future of Weight Loss: Exploring Wegovy's Oral Breakthrough and Ongoing Controversies

Discover the groundbreaking developments surrounding Novo Nordisk's Wegovy in this informative podcast episode with Alexandra Reeves. Learn about the potential game-changing FDA approval of an oral semaglutide pill that could revolutionize obesity treatment, delivering impressive 16.6% average weight loss in clinical trials. Reeves expertly analyzes how this once-daily alternative to weekly injections could expand accessibility while addressing the complex landscape of soaring demand, supply shortages, and concerning safety signals. The episode delves into mounting litigation surrounding reported side effects, recent studies linking semaglutide to increased blood clot...

# Podcast Episode: The Wegovy Revolution - Reshaping Lives and Modern Medicine

Discover the groundbreaking impact of Wegovy, the obesity medication taking the medical world by storm, in this informative episode with Alexandra Reeves. Explore how this weekly injection is transforming weight management and mental wellbeing for millions struggling with obesity.

The episode dives into the latest INFORM survey results, revealing Wegovy's impressive ability to reduce "food noise" by 46% and improve mental wellbeing in 64% of users. Learn about Novo Nordisk's plans for a high-dose version to compete with Eli Lilly's Zepbound, and Wegovy's recent FDA approval for...

# FDA Approves Wegovy for MASH: A Groundbreaking Moment in Metabolic Medicine

Discover the game-changing FDA approval of Wegovy for MASH (fatty liver disease) in this comprehensive podcast episode. Host Alexandra Reeves explores how this GLP-1 medication is transforming from a weight loss solution to a multi-condition treatment option, offering hope to millions with limited alternatives.

The episode delves into Novo Nordisk's strategic moves, including their upcoming oral Wegovy formulation and next-generation amycretin molecule, alongside recent workforce reductions of 9,000 jobs. Learn about the mounting legal challenges facing Wegovy, with over 2,000 cases related to gastrointestinal injuries and potential...

# Wegovy vs. the Competition: New Study Shows Remarkable Cardiovascular Benefits | Health Horizons Podcast

Explore the groundbreaking developments surrounding Wegovy (semaglutide) in this insightful episode of Health Horizons with Alexandra Reeves. Discover how recent research at the European Society of Cardiology Congress revealed Wegovy reduced cardiovascular risks by an impressive 57% compared to rival medications. We dive into the scientific findings, regulatory challenges, and accessibility concerns affecting millions of patients seeking weight management solutions.

Learn about the FDA's new import regulations targeting unapproved GLP-1 ingredients, the class-action lawsuit against CVS Caremark, and what the pending oral Wegovy approval...

# Wegovy's Medical Breakthrough: New Heart Protection Data and MASH Approval Revolutionize Treatment Options

In this eye-opening episode of Alexandra Reeves' medical podcast, discover the latest groundbreaking developments surrounding Novo Nordisk's Wegovy. Learn how this GLP-1 medication is transforming from a weight loss drug into a multi-purpose treatment with significant cardiovascular benefits and a new FDA approval for metabolic dysfunction-associated steatohepatitis (MASH).

Alexandra unpacks the stunning results from the STEER study presented at the 2025 European Society of Cardiology Congress, revealing Wegovy's remarkable 57% reduction in major cardiovascular events compared to rival drug Tirzepatide (Zepbound). The episode also explores...

# Wegovy's Groundbreaking Expansion: From Weight Management to Revolutionary Liver Disease Treatment

Discover how Wegovy (semaglutide) is transforming healthcare beyond weight loss. In this eye-opening podcast episode, medical correspondent Alexandra Reeves examines Novo Nordisk's FDA-approved breakthrough for treating MASH (metabolic dysfunction-associated steatohepatitis), a serious liver condition affecting 22 million Americans. Learn how this GLP-1 agonist achieved remarkable clinical results with nearly 37% of patients showing improved liver fibrosis and 63% experiencing steatohepatitis resolution. The episode also covers Wegovy's expanding applications for cardiovascular health, new affordability programs at $499/month for self-paying patients, and innovative telehealth access options. From regulatory milestones to accessibility challenges...

# Wegovy's Expanding Impact: From Weight Loss to Groundbreaking MASH Treatment

Explore the latest breakthrough for Wegovy as host Alexandra Reeves dives deep into the FDA's recent approval of this revolutionary GLP-1 medication for treating MASH (metabolic dysfunction-associated steatohepatitis). Discover how this Danish pharmaceutical innovation is transforming treatment options for 15 million Americans suffering from this serious liver condition, with clinical trials showing disease resolution in nearly two-thirds of patients.

This episode unpacks Wegovy's remarkable evolution from weight management drug to a multi-purpose treatment now proven to protect heart health and liver function. Learn about the science behind...

# Wegovy's Groundbreaking FDA Approval for MASH: A New Era in Liver Disease Treatment

Discover how Wegovy, the popular weight loss medication, has received FDA approval for treating metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition affecting up to 22 million Americans. In this insightful episode, Alexandra Reeves explores the revolutionary impact of this first-of-its-kind approval and what it means for patients worldwide.

Learn about the impressive clinical trial results showing that more than 60% of patients using Wegovy experienced resolution of steatohepatitis without worsening liver fibrosis—nearly double the placebo group's results. We examine how this GLP-1 therapy is...

# FDA Approves Wegovy for MASH Treatment: A Game-Changer for Liver Disease

Discover how Wegovy, Novo Nordisk's weight management drug, received FDA approval for treating MASH (metabolic dysfunction-associated steatohepatitis) in adults with moderate to advanced liver fibrosis. Host Alexandra Reeves breaks down this groundbreaking development that transforms Wegovy from a weight loss medication into a powerful treatment for chronic liver disease. Learn about the impressive clinical trial results showing 63% MASH resolution rate compared to just 34% with placebo, and how this approval creates a $50 billion market opportunity. The episode explores Novo Nordisk's strategic expansion of semaglutide applications, potential oral formulations...

# The Wegovy Revolution: Access, Competition, and Navigating Weight Management Medicine

In this compelling episode of our podcast, we delve into the rapidly evolving landscape of weight management medicine, focusing on Novo Nordisk's groundbreaking drug Wegovy. Host Alexandra Reeves guides listeners through recent developments that impact healthcare access, market dynamics, and patient decisions.

Discover how Wegovy secured preferred status on CVS Health Caremark's national formulary, potentially transforming access for tens of millions of Americans. We explore the intensifying competition between Novo Nordisk and Eli Lilly, along with the concerning rise of compounded semaglutide alternatives despite FDA warnings.<...

# Inside the Wegovy Revolution: How Novo Nordisk's Weight Loss Drug Is Reshaping Healthcare

Dive into the latest developments surrounding Wegovy, the groundbreaking weight loss medication that's become a cultural phenomenon beyond the pharmaceutical world. This episode explores Novo Nordisk's recent insurance victory with CVS Health Caremark, impressive financial growth despite challenges from knockoff drugs, and the ongoing legal battle against compounded versions of semaglutide.

We examine the FDA's warnings about unauthorized compounded GLP-1 medications and reveal Novo Nordisk's next potential game-changer: an oral version of Wegovy showing promising 13.6% weight loss in clinical trials. Learn how this...

# Wegovy's Weight Loss Revolution: Market Tumult, Legal Battles, and New Contenders

Explore the rapidly evolving landscape of weight-loss medications as host Alexandra Reeves dives deep into Wegovy's dramatic journey. This episode unpacks Novo Nordisk's recent 20% stock plunge amid rising competition from compounded semaglutide alternatives, despite the official end to medication shortages. Learn about the concerning wave of lawsuits alleging undisclosed side effects, including a 250% increase in blood clot risks according to new research. Discover how telehealth is transforming access to these medications while insurance barriers persist for millions. The episode also examines promising innovations including Eli Lilly's new...

# Wegovy in Focus: The Weight Loss Revolution Transforming Healthcare

Dive into the latest episode of Alexandra Reeves' investigative podcast exploring Wegovy, the groundbreaking weight loss medication reshaping healthcare and society. With over 30 years of global reporting experience, Reeves examines the profound impact of this GLP-1 medication that helps patients lose an average of 15% body weight—far surpassing traditional methods.

This episode unpacks recent developments including:
- CVS Caremark's controversial decision to remove competitor Zepbound in favor of Wegovy
- The end of medication shortages and FDA crackdown on compounded versions
- New research re...

# Weight Loss Revolution: Wegovy's Market Impact, Legal Battles, and Health Implications

Discover the latest developments in the world of weight management as host Alexandra Reeves explores Wegovy's evolving story. This episode dives into Novo Nordisk's recent financial challenges, the growing controversy over counterfeit GLP-1 medications, and the legal battles reshaping the weight loss drug landscape.

Learn how pharmacy benefit managers like CVS Caremark are changing patient access, why lawmakers are demanding stricter FDA oversight, and what new research reveals about Wegovy's long-term effectiveness. Beyond weight loss, discover emerging applications for semaglutide in treating alcohol use disorder...

# The Wegovy Revolution: Transforming Obesity Treatment Amid Counterfeits, Rebounds, and New Medical Frontiers

Dive into the groundbreaking world of Wegovy, the weight-loss medication reshaping obesity treatment. Alexandra Reeves explores the dramatic impact of semaglutide injections, which help patients lose up to 15% of body weight in clinical trials. Learn about the dangerous counterfeit market emerging as demand outpaces supply, with 80+ lawmakers urging FDA action against potentially harmful knockoffs. This episode unpacks the "Ozempic rebound" phenomenon where patients regain weight after stopping treatment, and reveals exciting new medical frontiers as researchers explore Wegovy's potential for treating alcohol use disorder and...

# Wegovy: Miracle Weight Loss Drug or Problematic Solution? - Health News Podcast

Join Alexandra Reeves in this eye-opening episode exploring Wegovy's extraordinary rise in popularity and its wide-ranging impacts. Discover how this injectable semaglutide medication has transformed obesity treatment while creating significant challenges - from nationwide shortages affecting 25,000 new weekly patients to alarming legal battles over serious side effects including blood clots, vision loss, and digestive injuries.

The episode dives deep into global access issues, with governments worldwide struggling to determine coverage policies while patients face high costs and limited availability. Learn about the sobering reality...

# Wegovy's Impact: Blockbuster Weight-Loss Drug Faces Access Challenges Despite Soaring Demand

In this insightful episode of Global Dispatch, host Alexandra Reeves examines the meteoric rise of Wegovy, the groundbreaking weight-loss medication that has transformed both the pharmaceutical industry and public health conversations. Discover how this GLP-1 drug generated nearly $1.9 billion in US sales alone last quarter—an 83% year-over-year increase—while still remaining inaccessible to millions of Americans due to insurance gaps and high costs.

The episode explores the complex landscape surrounding Wegovy, including supply chain challenges, FDA warnings about unregulated compounded versions, and the ongoing competition with...

# Wegovy's Evolution: Higher Doses, Greater Weight Loss, and the Changing Landscape of Obesity Treatment

Discover the latest breakthroughs in obesity management as host Alexandra Reeves explores Novo Nordisk's application for a stronger 7.2mg Wegovy dose. Learn how clinical trials show unprecedented weight loss results—up to 21% of total body weight—rivaling bariatric surgery outcomes. This episode dives into the science behind GLP-1 medications, practical lifestyle strategies for patients, accessibility challenges, and the competitive landscape between Wegovy and Zepbound. Gain insights into how these medications are transforming obesity treatment while navigating real-world concerns about cost, insurance coverage, and the impo...

# Breaking News: Wegovy's Game-Changing 7.2mg Dose & The Future of Obesity Treatment

Join host Alexandra Reeves as she unpacks the latest breakthrough in weight loss medication: Novo Nordisk's submission of a powerful new 7.2mg Wegovy dose to European regulators. This episode explores the STEP UP clinical trials showing remarkable 21% average weight loss results, with one-third of participants losing a quarter of their body weight.

Discover how this pharmaceutical innovation impacts obesity treatment globally, from new oral formulations pending FDA approval to strategic partnerships with WeightWatchers enhancing accessibility. Alexandra analyzes the competitive landscape between Wegovy and Eli Lilly's...

# The Wegovy Revolution: From Lab Promise to Global Health Game-Changer

Discover the extraordinary journey of Wegovy, the weight-loss medication transforming millions of lives worldwide. In this eye-opening episode, Alexandra Reeves explores how semaglutide evolved from scientific footnote to household name, examining Novo Nordisk's bold move to introduce a high-dose 7.2mg version to European regulators that could generate billions in additional revenue.

Learn how this groundbreaking medication helps patients lose an average of 15% body weight while revolutionizing treatment approaches for both obesity and type 2 diabetes. The episode delves into the mounting legal challenges as lawsuits spotlight potential...

# The Wegovy Revolution: How This Weight Loss Treatment is Reshaping Health in 2025

Explore the groundbreaking impact of Wegovy (semaglutide) on global healthcare and obesity treatment in this insightful podcast episode with Alexandra Reeves. Discover how this former diabetes medication transformed into a weight loss phenomenon that's making headlines from London to Singapore.

This episode dives deep into Wegovy's remarkable journey - from its clinical success with millions of NHS prescriptions to emerging legal challenges in American courtrooms. Learn about the latest scientific breakthroughs, including potential oral formulations and combination therapies showing unprecedented 30% weight loss results.
<...

# Breaking News: Wegovy & Obesity Treatment Shake-up | Quiet Please Podcast

Join veteran global reporter Alexandra Reeves as she unpacks the latest dramatic developments in the world of obesity treatment. In this must-listen episode, discover why pharmaceutical giant Novo Nordisk abruptly ended its partnership with telehealth provider Hims and Hers over allegations of counterfeit Wegovy products. Learn about groundbreaking clinical research unveiled at the American Diabetes Association summit, including Eli Lilly's bimagrumab combination therapy that preserves muscle while maximizing fat loss. Alexandra explores Wegovy's higher-dose formulation showing 21% average weight loss, important safety considerations, and what these developments mean for millions...

# The Wegovy Revolution: How a Single Drug is Reshaping Healthcare, Economics, and Society

Join host Alexandra Reeves as she explores the unprecedented impact of Wegovy beyond weight loss. This eye-opening episode reveals how Novo Nordisk's blockbuster medication is transforming multiple industries worldwide—from a patent protection lapse in Canada to its groundbreaking FDA approval for cardiovascular protection. Discover the latest developments in oral formulations, supply chain challenges, and emerging legal controversies surrounding this $28 billion phenomenon. Learn how Wegovy has grown from a simple weight management tool into a cultural force so powerful it's now worth more than Denmark's en...

# Wegovy: Transforming Weight Loss & Heart Health - with Alexandra Reeves

Join veteran international correspondent Alexandra Reeves as she explores Wegovy, the groundbreaking medication revolutionizing obesity treatment and cardiovascular health. This episode dives into Wegovy's dual impact: significant weight loss benefits and its FDA approval for reducing serious heart problems in adults with cardiovascular disease and obesity.

Discover how increased accessibility is changing lives as the FDA declares the Wegovy shortage resolved in 2025, while Novo Nordisk implements new pricing initiatives for self-pay patients. Alexandra examines the medication's growing popularity among teens, where prescriptions have increased by 50% in...

# Wegovy Breakthrough: The Future of Obesity Treatment Explored

Discover the latest developments in obesity care as veteran journalist Alexandra Reeves examines Wegovy's impact on healthcare worldwide. This insightful episode delves into recent pricing announcements, emerging legal challenges, and breakthrough research that's reshaping weight management treatment.

Listen as Reeves unpacks critical updates including Novo Nordisk's temporary $499 pricing strategy, the growing number of lawsuits surrounding GLP-1 medications, and new safety warnings from European regulators. The episode also explores exciting innovations on the horizon—from higher-dose formulations to the potential game-changing oral version of Wegovy expected later this year.

# Wegovy: The Science, Business, and Human Experience Behind a Transformative Weight Loss Drug

Join host Alexandra Reeves as she takes you beyond the headlines to explore the multifaceted world of Wegovy, one of the decade's most significant weight loss medications. This comprehensive episode examines recent developments including rare eye condition warnings from European regulators, the dramatic rise in teenage prescriptions, temporary price reductions, and the potential game-changing FDA application for an oral version of the drug.

Discover how this GLP-1 receptor agonist is reshaping obesity treatment while navigating controversy and personal impact. Reeves provides expert analysis...

# The Latest on Wegovy: Breaking Developments in Weight Loss Medication - Podcast Episode Description

Dive into the latest breaking news surrounding Wegovy, the groundbreaking weight loss medication that's transforming the healthcare landscape in 2025. In this informative episode, host Alexandra Reeves delivers comprehensive coverage of crucial developments affecting millions of potential and current users.

Discover the European Medicines Agency's recent safety findings about a rare eye condition linked to semaglutide medications, and learn about Novo Nordisk's limited-time pricing offer making this typically expensive treatment more accessible at $499 through June. We explore the expansion of telehealth options for...

# Breaking News: Novo Nordisk Slashes Wegovy Prices as FDA Ends Compounding

In this timely episode, we explore Novo Nordisk's strategic move to temporarily reduce Wegovy pricing to $199 for the first month and $499 thereafter for new self-paying patients. This price cut coincides with the FDA ending its grace period for compounded GLP-1 medications, potentially reshaping access to weight loss treatments. We discuss the implications for patients seeking affordable options, with remarkable success stories highlighting Wegovy's effectiveness—87% of users losing over 10% of their body weight. Plus, get exclusive insights on Novo Nordisk's upcoming oral Wegovy formulation that could revolutionize obesity tr...

# Wegovy's Global Impact: Inside the Weight Loss Revolution

Explore the complex world of Novo Nordisk's groundbreaking weight loss drug Wegovy with veteran global health journalist Alexandra Reeves. This eye-opening episode delves into the recent federal ban on compounded semaglutide, Novo Nordisk's response with discounted patient offers, and the intensifying competition from Eli Lilly's Zepbound. Learn about the promising oral semaglutide pill awaiting FDA approval, leadership changes in Europe, and the ongoing challenges of accessibility and equity in obesity treatment. Discover how this revolutionary medication achieving 15% average weight loss is reshaping healthcare systems worldwide while navigating regulatory hurdles, scientific...